Get your full text copy in PDF
Hisamitsu Miyaaki, Mitsuhisa Takatsuki, Tatsuki Ichikawa, Masaaki Hidaka, Akihiko Soyama, Hideki Ohdan, Yukihiro Inomata, Shinji Uemoto, Norihiro Kokudo, Kazuhiko Nakao, Susumu Eguchi
(Department of Gastroenterology and Hepatology, Nagasaki University, Nagasaki City, Nagasaki, Japan)
Ann Transplant 2017; 22:701-706
In patients with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infection, HIV can modulate HCV replication and immune response as well as accelerate liver fibrosis. The role of miRNA in HIV/HCV co-infection is not fully elucidated. The aim of this study was to examine the differential expression of miRNAs in the liver.
MATERIAL AND METHODS: Thirteen patients who had undergone a liver transplant (7 HCV-infected and 6 HIV/HCV-co-infected patients) were examined using a miRNA array containing 1347 human miRNAs. To confirm the microarray results, data for 20 patients (10 HCV-infected and 10 HIV/HCV-co-infected) were validated using real-time polymerase chain reaction probing for miR101b, miR149, and miR200c. This miRNA was selected based on microarray results and its biological significance in liver fibrosis.
RESULTS: Microarray analysis revealed 22 miRNAs that were differentially expressed in the HIV/HCV-co-infected group compared to the HCV-infected group (p<0.05). The expression of miR-101b and miR149 was significantly decreased in the HIV/HCV-co-infected group compared to that in the HCV-infected group (miR101b, 0.103±0.09 vs. 0.0157±0.0093, p=0.007; miR149, 0.152±0.159 vs. 0.0192±0.015, p=0.025).
CONCLUSIONS: HIV/HCV co-infection may promote liver fibrosis by modulating miRNA expression.
Keywords: Hepatitis C Antibodies, Hepatitis, Viral, Human, Liver Cirrhosis